Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma
- 11 July 2008
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 51 (5) , 675-678
Abstract
Purpose: To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells.Patients and Methods: Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m2 plus melphalan 180 mg/m2.Results: Twenty‐nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow‐up of 7.5 years (range = 2.8–10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease.Conclusion: Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long‐term survivors. Pediatr Blood Cancer 2008;51:675–678.Keywords
This publication has 15 references indexed in Scilit:
- Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group StudyJournal of Clinical Oncology, 2007
- Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumorsCancer, 2007
- Pre‐radiation chemotherapy with response‐based radiation therapy in children with central nervous system germ cell tumors: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2007
- Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumorsCancer, 2006
- Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2006
- State of the art chemotherapeutic management of pediatric brain tumorsExpert Review of Neurotherapeutics, 2006
- Molecular Biology of Medulloblastoma: Will It Ever Make a Difference to Clinical Management?Journal of Neuro-Oncology, 2005
- Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy AloneNew England Journal of Medicine, 2005
- Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237.Neuro-Oncology, 2003
- Paclitaxel for the Treatment of Progressive or Recurrent Childhood Brain Tumors: A Pediatric Oncology Phase II StudyJournal of Pediatric Hematology/Oncology, 2001